Hepatocellular

Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Breakthrough Therapy Designation from FDA

For LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination Treatment as Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not…

5 years ago

WuXi STA and Antengene Sign Development and Manufacturing Agreement

Shanghai, July 24, 2018: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Antengene Corporation, a…

6 years ago

Bead Chemo Embolisation becoming the most preferred way of treatment for Liver cancer patients

This non-surgical revolutionary treatment has no side effects and higher survival rate, says Dr. Sandip Jhala, Interventional Specialist, Apollo Hospitals-Ahmedabad…

7 years ago